Advances and Progress in Drug Design

This event will focus on enabling biophysical tools and highlight key advancements in protein-based drug discovery, with new areas of discussion including: Small molecules in drug design - A look at novel inhibitors and favourable protein-fragment interactions.

Plus talks on strategic designs of compound libraries and data mining techniques will examine IMI Open PHACTS project as well as fragment deconstruction approaches and the result of halogen-mediated interactions.

Moreover, we will take a closer look at combined HTS and FBDD methods for lead generation and the application of biophysical methods such as: X-Ray Crystallography, NMR, biocore and ITC to aid the prioritization of target inhibitors.

Chair for 2016:

Gregg Seigal, Chief Executive Officer, ZoBio

Featured Speakers:

Tove Sjögren, Associate Director, AstraZeneca
Herman van Vlijmen, Senior Director, Janssen
Armin Ruf, Section Head, Biostructure, Roche
Gianni Chessari, Director, Astex Pharmaceuticals
Hans Matter, Senior Scientist, Sanofi-Aventis
Jordi Munoz Muriedas, Investigator, GSK
Manuel Francisco Molina-Martin, Research Scientist, Eli Lilly

Sponsored by: Chemical Computing Group, OpenEye Scientific Software